TAROPHEN 36 MG

Nazione: Israele

Lingua: inglese

Fonte: Ministry of Health

Compra

Scarica Foglio illustrativo (PIL)
08-08-2023

Principio attivo:

METHYLPHENIDATE HYDROCHLORIDE

Commercializzato da:

TARO INTERNATIONAL LTD, ISRAEL

Codice ATC:

N06BA04

Forma farmaceutica:

TABLETS EXTENDED RELEASE

Composizione:

METHYLPHENIDATE HYDROCHLORIDE 36 MG

Via di somministrazione:

PER OS

Tipo di ricetta:

Required

Prodotto da:

SUN PHARMACEUTICAL INDUSTRIES, INC,USA

Area terapeutica:

METHYLPHENIDATE

Indicazioni terapeutiche:

Treatment of Attention Deficit Hyperactivity Disorder (ADHD)

Data dell'autorizzazione:

2023-05-08

Foglio illustrativo

                                Patient leaflet in accordance with the Pharmacists' Regulations
(Preparations) – 1986
This medicine is dispensed with a doctor’s prescription only
Tarophen 18 mg
Tarophen 27 mg
Tarophen 36 mg
Tarophen 54 mg
Extended-release tablets
Active ingredient
Each Tarophen 18 mg tablet contains 18 mg methylphenidate
hydrochloride.
Each Tarophen 27 mg tablet contains 27 mg methylphenidate
hydrochloride.
Each Tarophen 36 mg tablet contains 36 mg methylphenidate
hydrochloride.
Each Tarophen 54 mg tablet contains 54 mg methylphenidate
hydrochloride.
Inactive ingredients and allergens in this medicine: see section 6
‘Additional
information’.
Read the entire leaflet carefully before you start using this
medicine.
This leaflet contains concise information about this medicine. If you
have any
further questions, consult your doctor or pharmacist.
This medicine has been prescribed for you. Do not pass it on to
others. It may
harm them, even if it seems to you that their medical condition is
similar to
yours.
1. What is this medicine intended for?
Tarophen is intended for the treatment of Attention Deficit
Hyperactivity
Disorder (ADHD) in children over the age of 6, adolescents, and adults
up to
the age of 65.
Therapeutic group: central nervous system stimulant.
Tarophen can improve attention and concentration, and reduce
impulsiveness
and hyperactivity in individuals with ADHD. Tarophen should be given
as part
of an ADHD treatment program that may include counseling or other
therapies.
2. Before using this medicine
Do not use this medicine if you or your child:
•
is sensitive (allergic) to the active ingredient (methylphenidate
hydrochloride) or to any of the other ingredients in this medicine
(see
section 6, ‘Additional information’).
•
is very anxious, mentally tense, or agitated (suffers from
restlessness)
•
has an eye problem called glaucoma (increased intraocular pressure)
•
has tics or Tourette's syndrome, or a family history of Tourette's
syndrome. Tics are involuntary repeated movements or sounds.
•
is 
                                
                                Leggi il documento completo
                                
                            

Documenti in altre lingue

Foglio illustrativo Foglio illustrativo arabo 08-08-2023
Foglio illustrativo Foglio illustrativo ebraico 08-08-2023

Cerca alert relativi a questo prodotto

Visualizza cronologia documenti